The use of CTLA4-specific human monoclonal antibodies like tremelimumab or ipilimumab to block the interaction between CTLA4 and B7 in order to increase T cell activation has been extensively utilized in clinical trials for patients with cancer, and the administration of tremelimumab to patients with metastatic melanoma has consistently induced objective tumor regression in approximately 10% of patients. This evidence concerns the gene CTLA4 and neoplasm.